| Literature DB >> 28503224 |
Ingrid Gatt1, Lorna M West2, Neville Calleja3, Charles Briffa4, Maria Cordina5.
Abstract
BACKGROUND: Investigating beliefs about medicines has been of interest over the past years, with studies aiming to better understand theoretical reasons behind development of such beliefs.Entities:
Keywords: Attitude to Health; Malta; Medication Adherence; Psychometrics; Reproducibility of Results; Surveys and Questionnaires
Year: 2017 PMID: 28503224 PMCID: PMC5386625 DOI: 10.18549/PharmPract.2017.01.886
Source DB: PubMed Journal: Pharm Pract (Granada) ISSN: 1885-642X
Procedure of translation and validation of the BMQ in the Maltese language
| Steps | Critical components |
|---|---|
| Preparation | Permission was obtained from Prof Robert Horne (the developer) for use of the instrument. He clarified ambiguities and provided a document on how to use and analyse the BMQ. This form of consultation was essential for better translation equivalence. |
| Forward translation | One independent forward translation was carried out using Maltese fonts by the principal investigator. Harmonisation of this initial translation was carried out with the Department of Translation at the University of Malta, where items were discussed within the context to be measured, in an attempt to avoid literal translations which can mislead the purpose of the study. At the same time, free translation was also avoided as it could wander too far from the meaning of the original. The translation was based on the SkoposTheory. |
| Reconciliation | The forward translation was discussed and revised for better harmonisation of concepts in the instrument, with the intention of capturing the conceptual meaning of the items. This was done through an expert panel in order to resolve discrepancies and allow for agreement between speech habits and preferences in the translated language. This functional approach in the translation was considered to respect the target patients and their situation and cultural background. |
| Back translation | The Maltese version was back translated to English by a certified translator who had no access to the original version of the BMQ, since reversibility is crucial to equivalence. |
| Back translation review | The back translation was reviewed against the English version so as to ensure conceptual equivalence of the translation carried out, avoiding mistranslations and translation losses which would render an incomplete replication of the source questionnaire in the target one. |
| Cognitive debriefing results and finalisation | Finalisation of the translation allowed for any necessary modifications or rewording of the items. Satisfactory review of comparison of both English versions (back translation and original) resulted in the finalisation of the Maltese language version of the BMQ. This editing process was needed to create a Maltese text which is maximally suitable for the intended patients. Improvements were considered necessary to fix problems which may hinder the mental processing of the questions, and to tailor these questions to the intended patients. |
| Proofreading | The draft in the Maltese language was checked for minor errors that might have been disregarded during the translation process by the principal investigator and a colleague. Conforming to the rules governing Maltese writing is important since it respects the general feeling of the people – errors in Maltese are often regarded as denigrating the language in the Maltese Islands |
| Final report (translation and validation) | The explanation of the process undertaken to effectively translate the BMQ into the Maltese language is presented in the results and discussion section under the section BMQ. |
Procedure as per Wild et al., 2005 - Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures.34
Demographic characteristics of study sample
| Diabetes (N=100) | Asthma (N=100) | Cardiac (N=100) | Depression (N=100) | Total (%) | |
|---|---|---|---|---|---|
| Gender | |||||
| Male | 51 | 44 | 60 | 37 | 48 |
| Female | 49 | 56 | 40 | 63 | 52 |
| Mean Age (SD) | 58 (15.83) | 50 (18.81) | 62 (19.04) | 53 (16.38) | 56 (18.13) |
| Age Range | 18-88 | 18-84 | 18-57 | 18-86 | 18-88 |
| Median | 62 | 51 | 68 | 54 | 60 |
| Education | |||||
| Primary | 34 | 20 | 42 | 31 | 31.8 |
| Secondary | 51 | 37 | 37 | 43 | 42.0 |
| Post-secondary | 8 | 20 | 8 | 14 | 12.5 |
| Tertiary (University) | 4 | 18 | 7 | 5 | 8.5 |
| Post Graduate | 2 | 3 | 1 | 0 | 1.5 |
| N/A | 1 | 2 | 5 | 7 | 3.8 |
| Occupation | |||||
| Employed | 14 | 38 | 24 | 13 | 22.3 |
| Unemployed | 12 | 13 | 4 | 31 | 15.0 |
| Housewife/stay-home dad | 17 | 11 | 6 | 18 | 13.0 |
| Pensioner | 53 | 32 | 64 | 31 | 45.0 |
| Other | 4 | 6 | 2 | 7 | 4.8 |
| Mean number of prescribed medicines (SD) / patient | |||||
| 3 (2.40) | 3 (1.74) | 5 (2.95) | 4 (2.54) | ||
| Mean Duration on medication in Years, (SD), (Range) | |||||
| 10 (9.33) (2 m - 46 y) | 17 (13.61) 2 m - 66 y) | 11 (11.25) (2 m - 53 y) | 17 (11.73) (2 m - 50 y) | ||
m: months; y: years
Cronbach alpha values obtained for different chronic illness groups within the Maltese population
| Asthmatic sample (N=100) | Diabetic sample (N=100) | Cardiac sample (N=100) | Depression sample (N=100) | Total (N=400) | Original study[ | |
|---|---|---|---|---|---|---|
| G1, G4, G7, G8 | 0.53 | 0.50 | 0.40 | 0.42 | 0.48 | 0.60-0.80 |
| G2, G3, G5, G6 | 0.49 | 0.57[ | 0.42 | 0.66 | 0.56[ | 0.47-0.83 |
| S1, S3, S4, S7, S10 | 0.80 | 0.67 | 0.72 | 0.71 | 0.73[ | 0.55-0.86 |
| S2, S5, S6, S8, S9 | 0.71 | 0.67 | 0.60 | 0.65 | 0.66[ | 0.63-0.80 |
Horne et al., 1999;
Sample taken on n=99,
Significant values for alpha
Re-calculated Cronbach alpha for the General- Overuse sub-scale for the chronic illness sample (N=400).
| BMQ (items per scale) | Items used | Cronbach alpha |
|---|---|---|
| BMQ General Overuse (3) | G1, G7, G8 | |
| BMQ General Overuse (3) | G1, G4, G7 | 0.37 |
Correlation (rho) between BMQ-General and BMQ-Specific Scales
| General Overuse | General Harm | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| G1 | G4 | G7 | G2 | G3 | G5 | ||||
| G4 | 0.093 | G3 | 0.226 | ||||||
| G7 | 0.311 | 0.096 | G5 | 0.166 | 0.176 | ||||
| G8 | 0.240 | 0.135 | 0.245 | G6 | 0.192 | 0.156 | 0.394 | ||
| S1 | S3 | S4 | S7 | S2 | S5 | S6 | S8 | ||
| S3 | 0.415 | S5 | 0.419 | ||||||
| S4 | 0.402 | 0.477 | S6 | 0.160 | 0.126 | ||||
| S7 | 0.376 | 0.417 | 0.364 | S8 | 0.342 | 0.238 | 0.132 | ||
| S10 | 0.140 | 0.258 | 0.274 | 0.182 | S9 | 0.411 | 0.387 | 0.223 | 0.354 |
Correlation significant at a level of 0.05 (2-tailed);
Correlation is significant at a level of 0.01 (2-tailed).
Principal component analysis using varimax rotation with Kaiser Normalisation. Eigenvalue > 1. BMQ-General items
| General Overuse | General Harm | Specific Necessity | Specific Concerns | ||
|---|---|---|---|---|---|
| 11.15 | 10.13 | 13.94 | 11.94 | ||
| G1 | It-tobba jużaw wisq mediċini | 0.651 | |||
| G4 | Rimedji naturali huma ta’ inqas periklu mill-mediċini | 0.238 | 0.446 | ||
| G7 | It-tobba jafdaw wisq fuq il-mediċini | 0.559 | |||
| G8 | Kieku t-tobba kellhom iktar ħin mal-pazjenti jiktbu inqas mediċini | 0.617 | |||
| G2 | Nies li jieħdu l-mediċini għandhom iwaqqfuhom għal ftit kull tant żmien | 0.608 | |||
| G3 | Ħafna mill-mediċini jwassluk biex tiddependi fuqhom | 0.440 | 0.392 | ||
| G5 | Il-mediċini jagħmlu iktar ħsara milli ġid | 0.604 | |||
| G6 | Il-mediċini kollha huma velenu | 0.690 | |||
Factor loadings >0.2 are reported
Principal component analysis using varimax rotation with Kaiser Normalisation. Eigenvalue > 1. BMQ- Specific items
| General Overuse | General Harm | Specific Necessity | Specific Concerns | ||
|---|---|---|---|---|---|
| 11.15 | 10.13 | 13.94 | 11.94 | ||
| S1 | Saħħti, fil-preżent, tiddependi mill-mediċini tiegħi | 0.728 | |||
| S3 | Kieku ħajti tkun impossibbli mingħajr il-mediċini tiegħi | 0.783 | |||
| S4 | Mingħajr il-mediċini tiegħi nkun marid/a ħafna | 0.750 | |||
| S7 | Saħħti fil-futur tiddependi fuq il-mediċini tiegħi | 0.704 | |||
| S10 | Il-mediċini tiegħi jipproteġuni milli nsir agħar | 0.396 | |||
| S2 | Li jkolli nieħu l-mediċini jinkwetani | 0.683 | |||
| S5 | Kultant ninkwieta dwar l-effetti fit-tul li jista’ jkollhom il-mediċini fuq saħħti | 0.660 | |||
| S6 | Il-mediċini tiegħi huma misteru għalija | 0.369 | 0.129 | ||
| S8 | Il-mediċini tiegħi jfixkluli ħajti | 0.449 | 0.432 | ||
| S9 | Kultant ninkwieta li nsir wisq niddependi fuq il-mediċini tiegħi | 0.743 | |||
Factor loadings >0.1 are reported
Principal component analysis carried out on individual sub-scales to confirm factor loading. No rotation. Eigenvalue >1.
| General Overuse | General Harm | Specific Necessity | Specific Concerns | ||
|---|---|---|---|---|---|
| G1 | Doctors use too many medicines | 0.729 | |||
| G4 | Natural remedies are safer than medicines | 0.323 | |||
| G7 | Doctors place too much trust on medicines | 0.718 | |||
| G8 | If doctors had more time with patients they would prescribe fewer medicines | 0.675 | |||
| G2 | People who take medicines should stop their treatment for a while every now and again | 0.598 | |||
| G3 | Most medicines are addictive | 0.541 | |||
| G5 | Medicines do more harm than good | 0.726 | |||
| G6 | All medicines are poisons | 0.737 | |||
| S1 | My health, at present, depends on my medicines | 0.748 | |||
| S3 | My life would be impossible without my medicines | 0.685 | |||
| S4 | Without my medicines I would be very ill | 0.379 | |||
| S7 | My health in the future will depend on my medicines | 0.630 | |||
| S10 | My medicines protect me from becoming worse | 0.764 | |||
| S2 | Having to take these medicines worries me | 0.728 | |||
| S5 | I sometimes worry about long-term effects of my medicines | 0.801 | |||
| S6 | My medicines are a mystery to me | 0.751 | |||
| S8 | My medicines disrupt my life | 0.715 | |||
| S9 | I sometimes worry about becoming too dependent on my medicines | 0.402 |
Factor loadings >0.3 reported
Comparisons of Internal consistency (alpha values) obtained in the Maltese study with the original and others published in different languages.
| General Overuse | General Harm | Specific Necessity | Specific Concerns | |
|---|---|---|---|---|
| Developer of BMQ (Horne | 0.60-0.80 | 0.47-0.83 | 0.55-0.86 | 0.63-0.80 |
| Portuguese (Salgado | - | - | 0.76 | 0.67 |
| German (Mahler | 0.80 | 0.79 | 0.83 | 0.83 |
| Italian (Argentero | - | - | 0.78 | 0.72 |
| Spanish (Tordera | 0.70 | 0.68 | 0.83 | 0.72 |
| Spanish (De las Cuevas | 0.75[ | 0.80 | 0.72 | |
| Maltese version of BMQ[ | 0.48 | 0.56 | 0.73 | 0.66 |
The original BMQ was developed using six chronic illness groups. Ranges of alpha are shown for all groups involved in the study.
Portuguese version analysed the BMQ-Specific for the general population of medicine users.
German version analysed the BMQ-General and BMQ-Specific across patients with a variety of chronic illnesses.
Italian version analysed BMQ-Specific in four chronic illness groups (asthma, diabetes, cardiovascular and depression).
Spanish version analysed BMQ-General and BMQ-Specific for a sample of asthmatic patients.
Spanish version analysed BMQ-General and BMQ-Specific in a sample of psychiatric patients and undergraduate students reading medicine and psychology (patients are tabulated).
Maltese version analysis was carried out using BMQ-General and BMQ-specific on four chronic illness groups (asthma, diabetes, cardiovascular and depression).
General items in the patient population gave a mono-factorial solution, therefore alpha was calculated on all 8-items together